Phase 1/2Data readout

Piktor (PI3K/mTOR Inhibitor)

HR+/HER2- Advanced Breast Cancer

SNSESensei Biotherapeutics

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: Piktor (PI3K/mTOR Inhibitor)
Development stage: Phase 1/2
Event type: Data readout
Indication: HR+/HER2- Advanced Breast Cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for Piktor (PI3K/mTOR Inhibitor) in HR+/HER2- Advanced Breast Cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

05/15/26:- FTH-PIK-101 first patient dosed. Interim Ph1b/2 data expected in 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Phase 1/2Data readout

Piktor (PI3K/mTOR Inhibitor)

HR+/HER2- Advanced Breast Cancer

SNSESensei Biotherapeutics

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: Piktor (PI3K/mTOR Inhibitor)
Development stage: Phase 1/2
Event type: Data readout
Indication: HR+/HER2- Advanced Breast Cancer

Research summary

What is being tracked?

Development notes

05/15/26:- FTH-PIK-101 first patient dosed. Interim Ph1b/2 data expected in 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Piktor (PI3K/mTOR Inhibitor)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs